192 related articles for article (PubMed ID: 36689620)
21. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
22. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
23. The signaling and the metabolic differences of various CAR T cell designs.
Razavi AS; Loskog A; Razi S; Rezaei N
Int Immunopharmacol; 2023 Jan; 114():109593. PubMed ID: 36700773
[TBL] [Abstract][Full Text] [Related]
24. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
25. The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.
Guruprasad P; Carturan A; Zhang Y; Cho JH; Kumashie KG; Patel RP; Kim KH; Lee JS; Lee Y; Kim JH; Chung J; Joshi A; Cohen I; Shestov M; Ghilardi G; Harris J; Pajarillo R; Angelos M; Lee YG; Liu S; Rodriguez J; Wang M; Ballard HJ; Gupta A; Ugwuanyi OH; Hong SJA; Bochi-Layec AC; Sauter CT; Chen L; Paruzzo L; Kammerman S; Shestova O; Liu D; Vella LA; Schuster SJ; Svoboda J; Porazzi P; Ruella M
Nat Immunol; 2024 Jun; 25(6):1020-1032. PubMed ID: 38831106
[TBL] [Abstract][Full Text] [Related]
26. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
27. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
[TBL] [Abstract][Full Text] [Related]
28. Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling.
Landoni E; Fucá G; Wang J; Chirasani VR; Yao Z; Dukhovlinova E; Ferrone S; Savoldo B; Hong LK; Shou P; Musio S; Padelli F; Finocchiaro G; Droste M; Kuhlman B; Shamshiev A; Pellegatta S; Dokholyan NV; Dotti G
Cancer Immunol Res; 2021 Apr; 9(4):441-453. PubMed ID: 33547226
[TBL] [Abstract][Full Text] [Related]
29. Design and Assessment of Novel Anti-CD30 Chimeric Antigen Receptors with Human Antigen-Recognition Domains.
Choi S; Pegues MA; Lam N; Geldres C; Vanasse D; Kochenderfer JN
Hum Gene Ther; 2021 Jul; 32(13-14):730-743. PubMed ID: 33287637
[TBL] [Abstract][Full Text] [Related]
30. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
[TBL] [Abstract][Full Text] [Related]
31. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.
Singh N; Frey NV; Engels B; Barrett DM; Shestova O; Ravikumar P; Cummins KD; Lee YG; Pajarillo R; Chun I; Shyu A; Highfill SL; Price A; Zhao L; Peng L; Granda B; Ramones M; Lu XM; Christian DA; Perazzelli J; Lacey SF; Roy NH; Burkhardt JK; Colomb F; Damra M; Abdel-Mohsen M; Liu T; Liu D; Standley DM; Young RM; Brogdon JL; Grupp SA; June CH; Maude SL; Gill S; Ruella M
Nat Med; 2021 May; 27(5):842-850. PubMed ID: 33888899
[TBL] [Abstract][Full Text] [Related]
32. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
[TBL] [Abstract][Full Text] [Related]
33. Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A; Sjöstrand M; Naik J; Mansilla-Soto J; Kefala D; Kladis G; Nianias A; Ruiter R; Poels R; Sarkar I; Patankar YR; Merino E; Reijmers RM; Frerichs KA; Yuan H; de Bruijn J; Stroopinsky D; Avigan D; van de Donk NWCJ; Zweegman S; Mutis T; Sadelain M; Groen RWJ; Themeli M
Sci Transl Med; 2021 Dec; 13(623):eabh1962. PubMed ID: 34878825
[TBL] [Abstract][Full Text] [Related]
34. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
35. CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells.
Guercio M; Orlando D; Di Cecca S; Sinibaldi M; Boffa I; Caruso S; Abbaszadeh Z; Camera A; Cembrola B; Bovetti K; Manni S; Caruana I; Ciccone R; Del Bufalo F; Merli P; Vinti L; Girardi K; Ruggeri A; De Stefanis C; Pezzullo M; Giorda E; Scarsella M; De Vito R; Barresi S; Ciolfi A; Tartaglia M; Moretta L; Locatelli F; Quintarelli C; De Angelis B
Haematologica; 2021 Apr; 106(4):987-999. PubMed ID: 32381575
[TBL] [Abstract][Full Text] [Related]
36. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
[TBL] [Abstract][Full Text] [Related]
38. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
[TBL] [Abstract][Full Text] [Related]
39. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
[TBL] [Abstract][Full Text] [Related]
40. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
